Rockwell Medical (RMTI) Stock Forecast, Price Target & Predictions
RMTI Stock Forecast
Rockwell Medical stock forecast is as follows: an average price target of $9.00 (represents a 131.36% upside from RMTI’s last price of $3.89) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
RMTI Price Target
The average price target for Rockwell Medical (RMTI) is $9.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential 131.36% upside from RMTI's last price of $3.89.
RMTI Analyst Ratings
According to 1 Wall Street analysts, Rockwell Medical's rating consensus is 'Buy'. The analyst rating breakdown for RMTI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Rockwell Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Raghuram Selvaraju | H.C. Wainwright | $9.00 | $3.19 | 181.91% | 131.36% |
| Jul 17, 2023 | Raghuram Selvaraju | H.C. Wainwright | $11.00 | $4.19 | 162.53% | 182.78% |
The latest Rockwell Medical stock forecast, released on Sep 04, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $9.00, which represents a 181.91% increase from the stock price at the time of the forecast ($3.19), and a 131.36% increase from RMTI last price ($3.89).
Rockwell Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $9.00 | $9.00 |
| Last Closing Price | $3.89 | $3.89 | $3.89 |
| Upside/Downside | -100.00% | 131.36% | 131.36% |
In the current month, the average price target of Rockwell Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rockwell Medical's last price of $3.89. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 17, 2023 | H.C. Wainwright | Buy | Buy | Hold |
Rockwell Medical's last stock rating was published by H.C. Wainwright on Sep 04, 2024. The company gave RMTI a "Buy" rating, the same as its previous rate.
Rockwell Medical Financial Forecast
Rockwell Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $23.77M | - | $19.67M | $19.31M | $18.69M | $18.68M | $16.12M | $45.94M | $15.99M | $15.14M | $15.47M | $15.16M | $15.28M | $15.90M | $15.86M | $15.49M | $15.41M | $14.85M | $15.56M | $14.95M | $14.59M |
| Avg Forecast | $28.25M | $27.63M | $27.17M | $25.91M | $25.16M | $26.50M | $22.91M | $21.70M | $22.63M | $22.85M | $18.08M | $19.12M | $16.30M | $19.37M | $16.80M | $18.80M | $17.65M | $18.18M | $18.22M | $17.24M | $15.66M | $15.67M | $14.41M | $15.55M | $16.22M | $15.98M | $16.39M | $16.90M | $19.03M | $12.97M |
| High Forecast | $28.25M | $27.63M | $27.17M | $25.91M | $25.16M | $26.50M | $22.91M | $21.70M | $22.63M | $22.85M | $18.08M | $19.12M | $16.30M | $19.37M | $16.80M | $18.80M | $17.65M | $18.18M | $18.22M | $17.24M | $15.66M | $15.67M | $14.41M | $15.55M | $16.22M | $15.98M | $16.39M | $16.90M | $22.83M | $15.57M |
| Low Forecast | $28.25M | $27.63M | $27.17M | $25.91M | $25.16M | $26.50M | $22.91M | $21.70M | $22.63M | $22.85M | $18.08M | $19.12M | $16.30M | $19.37M | $16.80M | $18.80M | $17.65M | $18.18M | $18.22M | $17.24M | $15.66M | $15.67M | $14.41M | $15.55M | $16.22M | $15.98M | $16.39M | $16.90M | $15.22M | $10.38M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | - | 1.03% | 1.18% | 0.96% | 1.11% | 0.86% | 2.60% | 0.88% | 0.83% | 0.90% | 0.97% | 0.97% | 1.10% | 1.02% | 0.95% | 0.96% | 0.91% | 0.92% | 0.79% | 1.13% |
Rockwell Medical's average Quarter revenue forecast for Dec 23 based on 1 analysts is $22.63M, with a low forecast of $22.63M, and a high forecast of $22.63M. RMTI's average Quarter revenue forecast represents a -4.78% decrease compared to the company's last Quarter revenue of $23.77M (Sep 23).
Rockwell Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-1.74M | - | $-1.20M | $-1.92M | $-3.07M | $-3.83M | $-5.97M | $-31.42M | $-7.66M | $-7.19M | $-6.56M | $1.17M | $-6.14M | $-5.82M | $-7.28M | $-6.66M | $-7.20M | $-9.60M | $-8.01M | $-6.40M | $-4.61M |
| Avg Forecast | $-9.76M | $-9.55M | $-9.39M | $-8.95M | $-8.69M | $-9.16M | $-7.92M | $-6.00M | $-7.82M | $-7.89M | $-6.25M | $-6.42M | $-37.40M | $-6.69M | $-5.81M | $-6.87M | $-6.10M | $-6.28M | $-6.29M | $-7.29M | $-5.41M | $-5.42M | $-4.98M | $-7.28M | $-5.61M | $-5.52M | $-5.66M | $-9.35M | $-7.77M | $-4.04M |
| High Forecast | $-9.76M | $-9.55M | $-9.39M | $-8.95M | $-8.69M | $-9.16M | $-7.92M | $-4.80M | $-7.82M | $-7.89M | $-6.25M | $-5.14M | $-29.92M | $-6.69M | $-5.81M | $-5.49M | $-6.10M | $-6.28M | $-6.29M | $-5.83M | $-5.41M | $-5.42M | $-4.98M | $-5.83M | $-5.61M | $-5.52M | $-5.66M | $-7.48M | $-6.22M | $-3.23M |
| Low Forecast | $-9.76M | $-9.55M | $-9.39M | $-8.95M | $-8.69M | $-9.16M | $-7.92M | $-7.20M | $-7.82M | $-7.89M | $-6.25M | $-7.71M | $-44.88M | $-6.69M | $-5.81M | $-8.24M | $-6.10M | $-6.28M | $-6.29M | $-8.74M | $-5.41M | $-5.42M | $-4.98M | $-8.74M | $-5.61M | $-5.52M | $-5.66M | $-11.22M | $-9.33M | $-4.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | - | 0.19% | 0.05% | 0.46% | 0.66% | 0.87% | 5.15% | 1.22% | 1.14% | 0.90% | -0.22% | 1.13% | 1.17% | 1.00% | 1.19% | 1.30% | 1.70% | 0.86% | 0.82% | 1.14% |
1 analysts predict RMTI's average Quarter EBITDA for Mar 21 to be $-7.29M, with a high of $-5.83M and a low of $-8.74M. This is -724.65% lower than Rockwell Medical's previous annual EBITDA (Dec 20) of $1.17M.
Rockwell Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | $-1.87M | - | $-2.46M | $-2.75M | $-4.67M | $-5.45M | $-7.70M | $-35.03M | $-7.58M | $-8.40M | $-7.75M | $-8.66K | $-7.35M | $-6.89M | $-7.98M | $-7.30M | $-7.86M | $-10.29M | $-8.68M | $-6.53M | $-4.74M |
| Avg Forecast | $1.12M | $800.84K | $480.51K | $-345.96K | $320.34K | $320.34K | $-1.12M | $-7.21M | $-2.24M | $-3.36M | $-3.84M | $-7.71M | $-38.84M | $-15.54M | $-25.95M | $-8.25M | $-31.71M | $-26.43M | $-28.19M | $-8.61M | $-29.95M | $-35.24M | $-49.33M | $-7.98M | $-43.46M | $-56.38M | $-59.02M | $-10.12M | $-7.93M | $-4.15M |
| High Forecast | $1.12M | $800.84K | $480.51K | $-345.96K | $320.34K | $320.34K | $-1.12M | $-5.77M | $-2.24M | $-3.36M | $-3.84M | $-6.17M | $-31.07M | $-15.54M | $-25.95M | $-6.60M | $-31.71M | $-26.43M | $-28.19M | $-6.89M | $-29.95M | $-35.24M | $-49.33M | $-6.39M | $-43.46M | $-56.38M | $-59.02M | $-8.10M | $-6.34M | $-3.32M |
| Low Forecast | $1.12M | $800.84K | $480.51K | $-345.96K | $320.34K | $320.34K | $-1.12M | $-8.65M | $-2.24M | $-3.36M | $-3.84M | $-9.25M | $-46.61M | $-15.54M | $-25.95M | $-9.90M | $-31.71M | $-26.43M | $-28.19M | $-10.34M | $-29.95M | $-35.24M | $-49.33M | $-9.58M | $-43.46M | $-56.38M | $-59.02M | $-12.15M | $-9.51M | $-4.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.56% | - | 0.32% | 0.07% | 0.30% | 0.21% | 0.93% | 1.10% | 0.29% | 0.30% | 0.90% | 0.00% | 0.21% | 0.14% | 1.00% | 0.17% | 0.14% | 0.17% | 0.86% | 0.82% | 1.14% |
Rockwell Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RMTI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Rockwell Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.44M | - | $3.75M | $4.15M | $4.02M | $5.30M | $4.27M | $15.66M | $5.42M | $5.14M | $5.77M | $6.55M | $5.29M | $4.87M | $7.35M | $6.56M | $6.45M | $7.72M | $9.32M | $5.06M | $6.10M |
| Avg Forecast | $9.22M | $9.02M | $8.87M | $8.45M | $8.21M | $8.65M | $7.48M | $4.30M | $7.39M | $7.45M | $5.90M | $4.60M | $5.32M | $6.32M | $5.48M | $4.92M | $5.76M | $5.93M | $5.94M | $6.42M | $5.11M | $5.11M | $4.70M | $7.35M | $5.29M | $5.22M | $5.35M | $10.88M | $6.15M | $5.34M |
| High Forecast | $9.22M | $9.02M | $8.87M | $8.45M | $8.21M | $8.65M | $7.48M | $5.16M | $7.39M | $7.45M | $5.90M | $5.52M | $5.32M | $6.32M | $5.48M | $5.90M | $5.76M | $5.93M | $5.94M | $7.70M | $5.11M | $5.11M | $4.70M | $8.82M | $5.29M | $5.22M | $5.35M | $13.05M | $7.38M | $6.41M |
| Low Forecast | $9.22M | $9.02M | $8.87M | $8.45M | $8.21M | $8.65M | $7.48M | $3.44M | $7.39M | $7.45M | $5.90M | $3.68M | $5.32M | $6.32M | $5.48M | $3.94M | $5.76M | $5.93M | $5.94M | $5.13M | $5.11M | $5.11M | $4.70M | $5.88M | $5.29M | $5.22M | $5.35M | $8.70M | $4.92M | $4.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.46% | - | 0.81% | 0.78% | 0.64% | 0.97% | 0.87% | 2.72% | 0.91% | 0.87% | 0.90% | 1.28% | 1.03% | 1.04% | 1.00% | 1.24% | 1.24% | 1.44% | 0.86% | 0.82% | 1.14% |
Rockwell Medical's average Quarter SG&A projection for Dec 23 is $7.39M, based on 1 Wall Street analysts, with a range of $7.39M to $7.39M. The forecast indicates a 114.39% rise compared to RMTI last annual SG&A of $3.44M (Sep 23).
Rockwell Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.07 | - | $-0.13 | $-0.24 | $-0.44 | $-0.62 | $-0.90 | $-4.10 | $-0.89 | $-0.99 | $-0.91 | $-0.00 | $-1.13 | $-1.09 | $-1.30 | $-1.25 | $-1.35 | $-1.94 | $-1.67 | $-1.40 | $-1.03 |
| Avg Forecast | $0.04 | $0.03 | $0.01 | $-0.01 | $0.01 | $0.01 | $-0.04 | $-0.04 | $-0.07 | $-0.10 | $-0.12 | $-0.17 | $-0.39 | $-0.48 | $-0.81 | $-0.99 | $-0.99 | $-0.82 | $-0.88 | $-0.99 | $-0.94 | $-1.10 | $-1.54 | $-1.43 | $-1.36 | $-1.76 | $-1.84 | $-1.98 | $-0.17 | $-0.07 |
| High Forecast | $0.04 | $0.03 | $0.01 | $-0.01 | $0.01 | $0.01 | $-0.04 | $-0.04 | $-0.07 | $-0.10 | $-0.12 | $-0.17 | $-0.39 | $-0.48 | $-0.81 | $-0.99 | $-0.99 | $-0.82 | $-0.88 | $-0.99 | $-0.94 | $-1.10 | $-1.54 | $-1.43 | $-1.36 | $-1.76 | $-1.84 | $-1.98 | $-0.14 | $-0.06 |
| Low Forecast | $0.04 | $0.03 | $0.01 | $-0.01 | $0.01 | $0.01 | $-0.04 | $-0.04 | $-0.07 | $-0.10 | $-0.12 | $-0.17 | $-0.39 | $-0.48 | $-0.81 | $-0.99 | $-0.99 | $-0.82 | $-0.88 | $-0.99 | $-0.94 | $-1.10 | $-1.54 | $-1.43 | $-1.36 | $-1.76 | $-1.84 | $-1.98 | $-0.20 | $-0.08 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | - | 0.79% | 0.62% | 0.91% | 0.77% | 0.91% | 4.14% | 1.08% | 1.12% | 0.92% | 0.00% | 1.02% | 0.71% | 0.91% | 0.92% | 0.77% | 1.06% | 0.84% | 8.24% | 14.70% |
According to undefined Wall Street analysts, Rockwell Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RMTI previous annual EPS of $NaN (undefined).
Rockwell Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.78 | $10.00 | 461.80% | - |
| EVOK | Evoke Pharma | $5.72 | $18.00 | 214.69% | Buy |
| RMTI | Rockwell Medical | $3.89 | $9.00 | 131.36% | Buy |
| AQST | Aquestive Therapeutics | $5.15 | $9.50 | 84.47% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| ITCI | Intra-Cellular Therapies | $86.17 | $94.50 | 9.67% | Buy |
| LFCR | Lifecore Biomedical | $5.99 | $6.50 | 8.51% | Buy |
| PAHC | Phibro Animal Health | $22.37 | $18.67 | -16.54% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
| GHSI | Guardion Health Sciences | $3.22 | $0.01 | -99.69% | Buy |
RMTI Forecast FAQ
Is Rockwell Medical a good buy?
Yes, according to 1 Wall Street analysts, Rockwell Medical (RMTI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RMTI's total ratings.
What is RMTI's price target?
Rockwell Medical (RMTI) average price target is $9 with a range of $9 to $9, implying a 131.36% from its last price of $3.89. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Rockwell Medical stock go up soon?
According to Wall Street analysts' prediction for RMTI stock, the company can go up by 131.36% (from the last price of $3.89 to the average price target of $9), up by 131.36% based on the highest stock price target, and up by 131.36% based on the lowest stock price target.
Can Rockwell Medical stock reach $6?
RMTI's average twelve months analyst stock price target of $9 supports the claim that Rockwell Medical can reach $6 in the near future.
What are Rockwell Medical's analysts' financial forecasts?
Rockwell Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $96.27M (high $96.27M, low $96.27M), average EBITDA is $-31.773M (high $-30.572M, low $-32.974M), average net income is $-7.69M (high $-6.248M, low $-9.132M), average SG&A $28.63M (high $29.49M, low $27.77M), and average EPS is $-0.055 (high $-0.055, low $-0.055). RMTI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $108.96M (high $108.96M, low $108.96M), average EBITDA is $-37.653M (high $-37.653M, low $-37.653M), average net income is $2.06M (high $2.06M, low $2.06M), average SG&A $35.55M (high $35.55M, low $35.55M), and average EPS is $0.0642 (high $0.0642, low $0.0642).
Did the RMTI's actual financial results beat the analysts' financial forecasts?
Based on Rockwell Medical's last annual report (Dec 2023), the company's revenue was $83.61M, beating the average analysts forecast of $82.67M by 1.14%. Apple's EBITDA was $-6.67M, missing the average prediction of $-28.384M by -76.50%. The company's net income was $-8.439M, missing the average estimation of $-17.161M by -50.82%. Apple's SG&A was $14.27M, missing the average forecast of $25.34M by -43.70%. Lastly, the company's EPS was $-0.0004, missing the average prediction of $-0.46 by -99.91%. In terms of the last quarterly report (Sep 2023), Rockwell Medical's revenue was $23.77M, beating the average analysts' forecast of $22.85M by 4.05%. The company's EBITDA was $-1.737M, missing the average prediction of $-7.895M by -78.00%. Rockwell Medical's net income was $-1.872M, missing the average estimation of $-3.364M by -44.34%. The company's SG&A was $3.44M, missing the average forecast of $7.45M by -53.79%. Lastly, the company's EPS was $-0.068, missing the average prediction of $-0.105 by -35.24%